胃がん診断の世界市場

胃がん診断の世界市場は2030年までに30億米ドルに到達

2024年に24億米ドルと推定される胃がん診断の世界市場は、2024年から2030年にかけてCAGR 3.5%で成長し、2030年には30億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである試薬・消耗品は、CAGR 2.8％を記録し、分析期間終了時には20億米ドルに達すると予測されます。機器セグメントの成長率は、分析期間中CAGR 4.8％と推定されます。

米国市場は6億6,450万米ドルと推定、中国はCAGR6.3％で成長予測

米国の胃がん診断市場は、2024年には6億6,450万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5億9,180万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.6%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界の胃がん診断市場- 主要動向と促進要因のまとめ

胃がん診断の進歩が早期発見と予後改善に不可欠なのはなぜか？

胃がんの早期発見は大きな課題です。病状が進行するまで症状が現れないことが多く、予後不良や生存率の低下につながります。しかし、胃がん診断の進歩が状況を変えつつあり、より早期で治療可能な段階で病気を発見することが可能になっています。その結果、胃がんが進行する前に発見できる診断技術の開発が重視されるようになってきました。内視鏡的超音波検査（EUS）や陽電子放射断層撮影（PET）などの画像診断技術の進化により、胃腫瘍の検出やその広がりを評価する能力が大幅に向上しました。さらに、診断プロセスにおいてバイオマーカー検査がますます重要となってきています。調査治療により、HER2、p53、CA19-9など、胃がんに関連するさまざまなバイオマーカーが同定され、臨床医がより正確に胃がんを発見し、分子プロファイルに基づいて治療計画を個別化するのに役立っています。血液サンプルから腫瘍DNAを分析する非侵襲的検査法であるリキッドバイオプシーも、診断能力を進歩させる画期的な方法です。このアプローチにより、侵襲的な処置を必要とすることなく、早期段階での発見と治療効果のモニタリングが可能になります。これらの技術革新は、早期発見の可能性を高めるだけでなく、根治治療の可能性を高め、患者の転帰と生存率を大幅に向上させるため、極めて重要です。早期診断の重要性が認識されるにつれ、研究開発への投資が増加し、胃がん検出の技術革新がさらに推進されています。

技術革新はどのように胃がん診断を変革しているのか？

技術革新は、胃がん診断をより効率的に、より正確に、よりアクセスしやすく変革する上で極めて重要な役割を果たしています。最も重要な開発のひとつは、画像技術の進歩です。内視鏡検査は、高精細カメラと狭帯域イメージング（NBI）や共焦点レーザー内視鏡（CLE）のような高度なイメージング技術を組み合わせることで、胃腫瘍や前がん病変を細胞レベルで可視化する能力を向上させました。これらの技術は、異常増殖の早期発見を可能にし、より精密な生検を可能にし、診断結果の精度を向上させています。さらに、人工知能（AI）と機械学習（ML）の登場により、画像診断の分析が大幅に強化され、より迅速で正確な胃がんの同定が可能になりました。AIアルゴリズムは現在、人間の目では見落とされる可能性のある画像データの微妙なパターンを検出するよう訓練することができ、放射線科医や病理医がより迅速で正確な診断を下すのに役立っています。次世代シークエンシング（NGS）技術の進歩により、胃がんの包括的な遺伝子プロファイリングが可能になり、分子診断学も急成長を遂げています。このアプローチにより、腫瘍の変異や遺伝子発現に関する貴重な知見が得られ、標的治療の指針となり、患者の転帰を改善することができます。さらに、血液サンプルから循環腫瘍DNA（ctDNA）を分析するリキッドバイオプシー技術は、非侵襲的診断に革命をもたらしています。この方法は、従来の生検法に代わる、より簡便で侵襲性の低い方法を提供し、胃がんを最も早期で治療可能な段階で発見することが期待されています。このような技術的飛躍的進歩は、胃がん診断のスピードと精度を向上させるだけでなく、より個別化された治療オプションのための基礎を築きつつあります。

胃がん診断ソリューションの需要を促進する主な要因は何か？

胃がん診断ソリューションに対する需要の高まりは、胃がんの世界の罹患率の上昇、ヘルスケアインフラの進歩、早期発見と個別化医療への注目の高まりなど、いくつかの要因によってもたらされています。胃がんの発生率は、食生活、ヘリコバクター・ピロリ感染、遺伝的素因などの要因により、多くの地域、特に東アジア、中央欧州、ラテンアメリカの一部で上昇すると予想されています。世界のヘルスケアシステムががん早期発見の重要性を認識するにつれ、より高度な診断技術への需要が高まっています。さらに、リキッドバイオプシーや内視鏡スクリーニングなどの非侵襲的・低侵襲的診断技術の採用が増加しており、患者にとっても医療従事者にとっても胃がん検出がより身近で費用対効果の高いものとなっています。世界中の政府や医療機関も、特に高リスク集団におけるがん検診プログラムの改善を推進しており、これが胃がん診断の需要をさらに促進しています。新興市場におけるヘルスケア・インフラの成長も重要な要因です。開発途上地域が高度な診断ツールにアクセスできるようになるにつれて、がんの予防、早期発見、治療に一層焦点が当てられるようになっています。個別化医療も市場の促進要因のひとつであり、患者ごとに最も効果的な治療戦略を特定するために、腫瘍の遺伝子検査や分子プロファイリングが一般的になってきています。さらに、胃がんに対する社会的認知度が高まるにつれ、胃がんが拡大する前に早期発見し、最終的に予後改善につながる診断薬に対する需要が高まっています。これらすべての要因が組み合わさって、胃がん診断ソリューションの需要増加を後押ししています。

胃がん診断市場成長の主な促進要因は？

胃がん診断市場の成長は、医療の進歩、世界のヘルスケア投資の増加、疾患に対する意識の高まりなど、さまざまな要因が絡み合ってもたらされます。胃がんの有病率が上昇を続ける中、特にリスクの高い地域では、予後を大幅に改善できる早期発見法に注目が集まっています。早期発見は依然として生存率を向上させる最も重要な要因の一つであり、そのため、治療が困難な後期段階に進行する前に病気を特定できる高度な診断ソリューションに対する需要が急増しています。分子診断や遺伝子診断の急速な開発も主な推進力であり、研究開発や臨床医が腫瘍をより正確にプロファイリングし、個々の患者に合わせた治療を行うためのツールを手に入れたからです。非侵襲的診断ツールとしてのリキッドバイオプシーの導入は、従来の生検よりも早期かつ安全に胃がんを発見する方法を提供することで、状況をさらに変えつつあります。さらに、AIを搭載した画像システムおよび高精細内視鏡を含む画像技術の進歩は、胃組織のより正確で詳細な評価を提供し、異常増殖および早期腫瘍の検出の改善を可能にしています。さらに、世界中のヘルスケアシステムが近代化し続ける中、特に新興市場では、こうした最先端の診断ツールへのアクセスがより広まりつつあります。特に高リスク集団における胃がん検診の重要性が認識されるようになったことで、診断技術への投資が官民ともに活発化しています。技術開発に加え、遺伝学的・分子学的データを活用した個別化治療計画への注目の高まりが、より正確でオーダーメイドの治療選択肢を提供できる診断薬への需要に拍車をかけています。このような要因によって技術革新と導入が促進され、胃がん診断市場は継続的な成長が見込まれており、世界中の患者の転帰と生存率が向上する可能性があります。

セグメント

製品タイプ（試薬・消耗品、機器）;疾患タイプ（腺がん、胃リンパ腫、その他の疾患タイプ）;エンドユーザー（病院、診断研究所、画像診断センター）

調査対象企業の例（注目の42社）

• Abbott Laboratories
• Agilent Technologies, Inc.
• BD（Becton, Dickinson and Company）
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Biohit Oyj
• CD Genomics
• DiaSorin S.p.A.
• Exalenz Bioscience Ltd.
• FUJIFILM Holdings Corporation
• GeneMatrix Inc.
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Invitae Corporation
• Labcorp Oncology
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• QIAGEN N.V.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Gastric Cancer Diagnostics Market to Reach US$3.0 Billion by 2030

The global market for Gastric Cancer Diagnostics estimated at US$2.4 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Reagents & Consumables, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$664.5 Million While China is Forecast to Grow at 6.3% CAGR

The Gastric Cancer Diagnostics market in the U.S. is estimated at US$664.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$591.8 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Gastric Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Are Advances in Gastric Cancer Diagnostics Crucial for Early Detection and Better Prognosis?

The early detection of gastric cancer is a major challenge, as symptoms often do not appear until the disease has progressed to later stages, leading to poor prognosis and low survival rates. However, advancements in gastric cancer diagnostics are changing the landscape, making it possible to detect the disease at earlier, more treatable stages. As a result, there has been a growing emphasis on developing diagnostic technologies that can identify gastric cancer before it reaches advanced stages. The evolution of imaging techniques, such as endoscopic ultrasound (EUS) and positron emission tomography (PET), has greatly improved the ability to detect gastric tumors and assess their spread. Moreover, biomarker testing is becoming increasingly prominent in the diagnostic process. Researchers have identified a range of biomarkers associated with gastric cancer, including HER2, p53, and CA 19-9, which are helping clinicians to detect the disease more accurately and to personalize treatment plans based on molecular profiles. Liquid biopsy, a non-invasive testing method that analyzes tumor DNA from blood samples, is another breakthrough that is advancing diagnostic capabilities. This approach enables early-stage detection and monitoring of treatment response without the need for invasive procedures. These innovations are crucial as they not only improve the chances of early detection but also offer better chances for curative treatment, significantly enhancing patient outcomes and survival rates. With growing recognition of the importance of early-stage diagnostics, there has been increased investment in research and development, further driving innovation in gastric cancer detection.

How Are Technological Innovations Transforming Gastric Cancer Diagnostics?

Technological innovations are playing a pivotal role in transforming gastric cancer diagnostics, making them more efficient, accurate, and accessible. One of the most significant developments has been the advancement in imaging technologies. Endoscopy, combined with high-definition cameras and advanced imaging techniques like narrow-band imaging (NBI) and confocal laser endomicroscopy (CLE), has improved the ability to visualize gastric tumors and precancerous lesions at the cellular level. These technologies allow for earlier detection of abnormal growths and enable more precise biopsies, improving the accuracy of diagnostic results. Furthermore, the advent of artificial intelligence (AI) and machine learning (ML) has significantly enhanced the analysis of diagnostic imaging, enabling more rapid and accurate identification of gastric cancer. AI algorithms can now be trained to detect subtle patterns in imaging data that may be missed by human eyes, helping radiologists and pathologists make faster and more accurate diagnoses. Molecular diagnostics are also seeing rapid growth, with advances in next-generation sequencing (NGS) technology allowing for comprehensive genetic profiling of gastric cancer. This approach provides valuable insights into tumor mutations and gene expression, which can guide targeted therapy and improve patient outcomes. Additionally, liquid biopsy technology, which involves analyzing circulating tumor DNA (ctDNA) from blood samples, is revolutionizing non-invasive diagnostics. This method offers a simpler, less invasive alternative to traditional biopsy procedures and holds promise for detecting gastric cancer in its earliest, most treatable stages. These technological breakthroughs are not only improving the speed and accuracy of gastric cancer diagnosis but are also laying the groundwork for more personalized treatment options.

What Are the Key Factors Driving the Demand for Gastric Cancer Diagnostic Solutions?

The growing demand for gastric cancer diagnostic solutions is driven by several factors, including the rising global incidence of gastric cancer, advancements in healthcare infrastructure, and the increasing focus on early detection and personalized medicine. The incidence of gastric cancer is expected to rise in many regions, particularly in East Asia, Central Europe, and parts of Latin America, due to factors such as diet, Helicobacter pylori infection, and genetic predisposition. As the global healthcare system recognizes the importance of early cancer detection, the demand for more advanced diagnostic technologies is increasing. Moreover, the increasing adoption of non-invasive and minimally invasive diagnostic techniques, such as liquid biopsy and endoscopic screening, is making gastric cancer detection more accessible and cost-effective for patients and healthcare providers alike. Governments and health organizations worldwide are also pushing for improved cancer screening programs, especially in high-risk populations, which is further fueling demand for gastric cancer diagnostics. The growth of healthcare infrastructure in emerging markets is another key factor. As developing regions gain access to advanced diagnostic tools, there is a greater focus on cancer prevention, early detection, and treatment. Personalized medicine is another driver of the market, as genetic testing and molecular profiling of tumors are becoming more common to identify the most effective treatment strategies for each patient. Furthermore, as public awareness of gastric cancer increases, there is greater demand for diagnostics that can detect the disease in its early stages before it spreads, which ultimately leads to better outcomes. All these factors combined are driving the increasing demand for gastric cancer diagnostic solutions.

What Are the Key Drivers Behind the Growth of the Gastric Cancer Diagnostics Market?

The growth of the gastric cancer diagnostics market is driven by a combination of factors related to medical advancements, increasing global healthcare investment, and rising awareness of the disease. As the prevalence of gastric cancer continues to rise, particularly in high-risk regions, there is an increased focus on early detection methods that can significantly improve prognosis. Early detection remains one of the most important factors in improving survival rates, which has led to a surge in demand for advanced diagnostic solutions that can identify the disease before it progresses to later, harder-to-treat stages. The rapid development of molecular and genetic diagnostics is another key driver, as researchers and clinicians now have the tools to more accurately profile tumors and tailor treatments to individual patients. The introduction of liquid biopsy as a non-invasive diagnostic tool is further transforming the landscape by offering a method for detecting gastric cancer earlier and more safely than traditional biopsies. Additionally, advancements in imaging technology, including AI-powered imaging systems and high-definition endoscopy, are providing more accurate and detailed assessments of gastric tissue, allowing for improved detection of abnormal growths and early-stage tumors. Furthermore, as healthcare systems across the globe continue to modernize, especially in emerging markets, access to these cutting-edge diagnostic tools is becoming more widespread. The increased recognition of the importance of gastric cancer screening, particularly in high-risk populations, has driven both public and private investments in diagnostic technologies. In addition to technological developments, the growing focus on personalized treatment plans that leverage genetic and molecular data has spurred the demand for diagnostics that can provide more precise and tailored treatment options. With these factors driving innovation and adoption, the gastric cancer diagnostics market is poised for continued growth, offering the potential for better outcomes and survival rates for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Gastric Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Reagents & Consumables, Instruments); Disease Type (Adenocarcinoma, Gastric Lymphoma, Other Disease Types); End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Agilent Technologies, Inc.
• BD (Becton, Dickinson and Company)
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Biohit Oyj
• CD Genomics
• DiaSorin S.p.A.
• Exalenz Bioscience Ltd.
• FUJIFILM Holdings Corporation
• GeneMatrix Inc.
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Invitae Corporation
• Labcorp Oncology
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• QIAGEN N.V.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Gastric Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Gastric Cancer Worldwide Drives Increased Demand for Advanced Diagnostic Solutions
  • Growing Awareness of Genetic and Lifestyle Factors Fuels Demand for Comprehensive Gastric Cancer Screening
  • Surge in Investment in Non-Invasive Diagnostic Technologies Expands Market Opportunities for Gastric Cancer Detection
  • Advancements in Liquid Biopsy and Molecular Diagnostics Drive Accuracy and Sensitivity in Early Diagnosis
  • Here's How the Integration of AI and Machine Learning in Diagnostic Tools is Enhancing Gastric Cancer Detection
  • Increased Adoption of Endoscopic Screening Methods Boosts Early Detection Rates and Market Growth
  • Growing Role of Biomarkers in Gastric Cancer Diagnostics Strengthens the Business Case for Precision Medicine
  • Rising Demand for Point-of-Care Diagnostics Expands Access to Early Gastric Cancer Detection in Remote Areas
  • Technological Innovations in Imaging and Optical Methods Enhance Diagnostic Precision and Minimize Invasiveness
  • Rising Focus on Multi-Omic Approaches, Including Genomic and Proteomic Profiling, Drives Diagnostic Advancements
  • Expanding Use of Companion Diagnostics for Personalized Treatment Planning in Gastric Cancer Strengthens Market Potential
  • Rising Focus on Early Detection in High-Risk Populations Creates Opportunities for Targeted Screening Solutions
  • Increased Demand for Integrated Healthcare Solutions and Data Analytics Platforms Enhances Gastric Cancer Diagnostic Accuracy
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gastric Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gastric Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Gastric Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Gastric Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Gastric Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Imaging Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Diagnostic Imaging Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Diagnostic Imaging Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• JAPAN
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• CHINA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• EUROPE
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Gastric Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• FRANCE
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• GERMANY
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• INDIA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Gastric Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Gastric Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030
• AFRICA
  • Gastric Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Gastric Cancer Diagnostics by Product - Reagents & Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Gastric Cancer Diagnostics by Product - Percentage Breakdown of Value Sales for Reagents & Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Gastric Cancer Diagnostics by Disease Type - Adenocarcinoma, Gastric Lymphoma and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Gastric Cancer Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Gastric Lymphoma and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Gastric Cancer Diagnostics by End-user - Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Gastric Cancer Diagnostics by End-user - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories and Diagnostic Imaging Centers for the Years 2015, 2025 & 2030

IV. COMPETITION